IIT Guwahati's Alumni-led Startup Introduces App To Diagnose Chronic Diseases At An Early Stage
Primary Healthtech, an Indian Institute of Technology Guwahati alumni-led start-up, has developed an indigenous point of care testing (POCT) device, MobilabTM, that is expected to test 25 parameters in blood to diagnose early chronic diseases related to kidney, liver, heart, and pancreas malfunctions.
The startup is incubated at the Research Park and the Centre for Nanotechnology in IIT Guwahati campus, with extensive R and D, translational, and regulatory support from SWASTHA Centre for Excellence of MeitY, ICMR-DHR Centre of Excellence and BIRAC-DBT.
The device is operated through an IoT-enabled Android app and can perform about 150 tests with a single charge of the battery, which enables a digitally connected ecosystem for its use even for the remotest locations of the nation and serves the last-mile population, the company said in its statement.
The device is expected to perform the early screening of Non-Communicable Diseases (NCDs), which contribute to around 41 million (74per cent) of deaths globally, as per the recent reports of the World Health Organization (WHO).
MobilabTM will enable testing at patients’ sites at a low cost to enable early screening as well as long-term disease management at an affordable cost for millions of people every year the company further stated.
Central Drugs Standard Control Organisation( CDSCO) has licenced manufacturing of MobilabTM which will include the Heart profile - Cholesterol, LDL, HDL and Triglycerides, Liver profile - Total Bilirubin, Albumin and Total Protein, Kidney profile - Creatinine, Glucose and Uric Acid Hematology - Haemoglobin Diabetic - Glucose
The device generates real-time data in 10 minutes, followed by a digital report, along with an electronic patient health record that can be easily shared with the doctors, the company's statement read.
Sahil Jagnani, Alumnus, of IIT Guwahati, and Founder & CEO, Primary Healthtech, said, “The vision of MobilabTM is to make diagnosis available to fellow citizens at an affordable cost, along with generating instant results to speed up the early screening, disease management, and treatment. MobilabTM is also expected to perform import substitution under the Make-in-India initiative of the Government of India."
